摘要
目的:系统评价他汀类药物治疗阿尔茨海默病(AD)的疗效。方法:通过计算机检索,全面收集他汀类药物治疗AD的随机对照试验,按Cochrane协作网系统评价的方法进行评价。结果:入选4项研究,共纳入1127例患者,其中他汀类药物组557例,安慰剂组570例。2组的AD评定量表-认知分量表(ADAS-Cog)评分与基线变化的比较,合并平均差(MD)为0.97,95%CI为(-0.84,2.78),简易精神状态量表(MMSE)评分与基线变化的比较,MD为0.88,95%CI为(-0.28,2.04),日常生活能力量表(ADL)评分与基线变化的比较,MD为-0.85,95%CI为(-3.50,1.80),神经精神症状问卷(NPI)评分与基线变化的比较,MD为-1.41,95%CI为(-3.47,0.65),差异均无统计学意义。结论:目前没有足够证据推荐他汀类药物用于治疗AD。
Obj Alzheimer＇ s Disease ective： To evaluate the efficacy of statins vs. （AD）. Methods： Randomized controlled tria concerning the comparison efficacy of statins vs. placebo in patient in the electronic bibliographic databases. Meta-analysis was condu ommended by the Cochrane Collaboration. Results： A total of 4 cli meta-analysis, and 1127 patients in total were randomly assigned and placebo group （570 cases）. Comparing the parameters bet groups, the ov mer＇s disease 2.04）] for in 1.80）] for aeti S placebo in the treatment of ls were collected. The trials with AD, have been searched cted based on the methods rec- nical trials were included in the into statins group （557 cases） ween the Statins and placebo erall mean difference were 0.97 [95%CI （-0.84, 2.78）] for the change in Alzhei assessment scale-cognitive （ADAS-Cog） from baseline, 0. 88 [ 95% mini-mentalstate examination （MMSE） from baseline, -0. 85 [95% vities of daily living （ADL） from baseline, and -1. 41195%CI （-3.47 neuropsychiatric recommend stati inveBtory （NPI） from baseline. Conclusion： There is insufficient ns for the
出处
《神经损伤与功能重建》
2012年第6期415-418,共4页
Neural Injury and Functional Reconstruction
关键词
他汀类药物
阿尔茨海默病
META分析
statins treatment of AD. Alzheimer＇ s disease
meta-analysis CI
